Apremilast, (+/-)-
| Code | Size | Price |
|---|
| TAR-T21043-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Apremilast, (+/-)-, is a small molecule inhibitor of phosphodiesterase 4 (PDE4) with oral activity. It is used to treat psoriatic arthritis.
CAS:
253168-86-4
Formula:
C22H24N2O7S
Molecular Weight:
460.5
Purity:
0.98
SMILES:
CCOc1cc(ccc1OC)C(CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O
References
1. Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. PubMed PMID: 28391657; PubMed Central PMCID: PMC5573969.
2. Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis. 2017 Feb;9(2):45-53. doi: 10.1177/1759720X16673786. Epub 2017 Jan 20. Review. PubMed PMID: 28255338; PubMed Central PMCID: PMC5315225.
3. Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1. Review. PubMed PMID: 28213862.
4. Mayba JN, Gooderham MJ. Real-World Experience With Apremilast in Treating Psoriasis. J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151. doi: 10.1177/1203475416676030. Epub 2016 Oct 23. PubMed PMID: 27846617.